Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Hainan Simcere Zaiming Pharmaceutical Co. Ltd. operates a highly focused prosecution profile within the Biotechnology & Pharmaceuticals technology area. The portfolio is currently limited to 2 pending office actions. This small number of active matters suggests a very specific or emerging interest in the United States patent system. These filings are split between 2 distinct art units, indicating that even with a minimal number of cases, the company is engaging with different specialized groups at the patent office.
The prosecution involves distinct examiners for each case, matching the count of pending actions exactly. SCHWECHTER, BRANDON ROSS is identified as the busiest examiner with 1 pending office action. Because there are so few pending office actions in total, the 1 pending office action assigned to this examiner constitutes a significant portion of the total pending office actions. The use of multiple distinct examiners across multiple distinct art units shows a complete lack of concentration, as every pending matter is handled by a different individual in a different administrative unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHWECHTER, BRANDON ROSS | 1 | 0.0% | +0.0% |
| JUEDES, AMY E | 1 | 44.7% | +41.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264486 | HUMAN CD33 ANTIBODY AND USE THEREOF | SCHWECHTER, BRANDON ROSS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275901 | HUMANIZED GPC3 ANTIBODY AND APPLICATION THEREOF | JUEDES, AMY E | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264486 | HUMAN CD33 ANTIBODY AND USE THEREOF | SCHWECHTER, BRANDON ROSS | 1674 | §112 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18275901 | HUMANIZED GPC3 ANTIBODY AND APPLICATION THEREOF | JUEDES, AMY E | 1644 | §102§112DP | Non-Final OA | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHainan Simcere Zaiming Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brandon Ross Schwechter has the most, with 1 of Hainan Simcere Zaiming Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
